Rapamycin (Sirolimus).

Leucine is the amino acid signal that switches mTORC1 on through the sestrin and Rag GTPase route, which is the exact complex this compound inhibits. Taken together they push the same node in opposite directions.

BCAA blends are leucine-led and activate mTORC1 signalling. That activation works against an mTOR inhibitor taken in the same window.

Whey is the most leucine-dense common protein and produces a sharp mTORC1 activation after intake. Timing matters if an mTOR inhibitor is in the same schedule.

HMB is a leucine metabolite that signals through the same mTORC1 axis. Its effect runs counter to mTOR inhibition.

St John's wort induces CYP3A4 and P-glycoprotein, the two systems that clear this compound. Blood levels fall substantially when the two are taken together.

Piperine inhibits CYP3A4 and P-glycoprotein in the gut wall, the same route that limits this compound's absorption. Exposure can rise unpredictably.

Quercetin inhibits P-glycoprotein and CYP3A4 at intakes reached with concentrated supplements. That can raise plasma levels of a narrow-window mTOR inhibitor.

Spermidine induces autophagy by inhibiting the acetyltransferase EP300, a route independent of mTOR. Both arrive at increased autophagic flux by separate entry points.

Resveratrol activates AMPK and sirtuin signalling, which suppresses mTORC1 from upstream. The signals converge on the same downstream node.

Berberine raises the AMP to ATP ratio and activates AMPK, which restrains mTORC1. It also inhibits CYP3A4, so the interaction runs on two channels at once.

Inulin is fermented by colonic bacteria to short-chain fatty acids, which shift the balance of regulatory and effector T cell populations. Rapamycin acts on the same immune compartment from the other end, through mTORC1 inhibition inside the cell. The RIVASTIM programme registered the pair as separate arms of a pilot randomised comparison rather than as a fixed combination, and the published documents are protocols, so no result should be read from them yet.

Blood levels of rapamycin track the activity of CYP3A4 and the P-glycoprotein efflux pump rather than the swallowed dose alone. Green tea catechins inhibit both in vitro, so a concentrated extract is a plausible source of level variation. The evidence here is mechanistic and laboratory-based, not a clinical measurement of the pair in people.

Silymarin flavonolignans inhibit CYP3A4 and several UGT enzymes in laboratory preparations. Because rapamycin clearance runs largely through CYP3A4, a standardised silymarin extract is a candidate for exposure change in either direction depending on dose and duration. No clinical measurement of the combination is being claimed.

Resistance exercise with creatine loading raises mTORC1 signalling in muscle, which is the same kinase complex rapamycin holds down through the FKBP12 complex. Anyone taking rapamycin for pathway reasons should know that a strong anabolic stimulus pushes the opposite way at the same node. Whether that matters at any given dose or timing has not been measured in people.

Iron availability influences mitochondrial function and the redox state that autophagy signalling responds to. In Drosophila, iron deficiency and rapamycin exposure interacted on antioxidant status, autophagy readouts and lifespan. This is a non-human observation on markers, and it does not carry across to human iron dosing.

Rapamycin dampens T cell proliferation, which is the reason it is used clinically. Live yeast and live bacterial preparations rely on an intact immune response to stay confined to the gut lumen. The pairing is one to raise with the prescriber rather than a synergy, and this row is a caution flag, not a recommendation.

Calcitriol signals through the vitamin D receptor to favour regulatory T cell phenotypes and supports normal immune cell function. Rapamycin reaches a similar cell population by holding mTORC1 down during T cell differentiation. The overlap is mechanistic and has not been quantified as a combination in people.

Ginkgo extracts have shown both inducing and inhibiting behaviour at CYP3A in different preparations, which makes the direction of any change unpredictable. Rapamycin blood levels depend on that enzyme, so unpredictability is the relevant point rather than a stated direction. Nothing here is a measured clinical interaction.